| Date Filed | Type | Description |
| 03/20/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 03/20/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/20/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/20/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/14/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/14/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/14/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/12/2019 |
4
| BROADWOOD PARTNERS, L.P. (See Remarks Below) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Disposed of 5,292,156 shares
@ $0 |
|
| 03/12/2019 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 0% stake in Asterias Biotherapeutics, Inc. |
| 03/08/2019 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 03/08/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/05/2019 |
4
| Wirth Edward (Chief Medical Officer) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Granted 156,452 shares
@ $0
Paid exercise price by delivering 48,826 shares
@ $0.95, valued at
$46.4k
|
|
| 03/05/2019 |
4
| Mulroy Michael H. (President and CEO) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Granted 252,606 shares
@ $0
Paid exercise price by delivering 76,588 shares
@ $0.95, valued at
$72.8k
|
|
| 03/05/2019 |
4
| Chavez Ryan Daniel (CFO and General Counsel) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Granted 145,263 shares
@ $0
Paid exercise price by delivering 44,471 shares
@ $0.95, valued at
$42.2k
|
|
| 03/01/2019 |
8-K
| Quarterly results |
| 03/01/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/28/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/04/2019 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 01/24/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/04/2019 |
4
| Chavez Ryan Daniel (CFO and General Counsel) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Paid exercise price by delivering 20,440 shares
@ $0.68, valued at
$13.9k
|
|
| 01/04/2019 |
4
| Wirth Edward (Chief Medical Officer) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Paid exercise price by delivering 20,440 shares
@ $0.68, valued at
$13.9k
|
|
| 12/06/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/06/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/04/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/09/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/09/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 11/08/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/08/2018 |
SC 13D/A
| BIOTIME INC reports a 39.2% stake in ASTERIAS BIOTHERAPEUTICS, INC. |
| 11/08/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/08/2018 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"AGREEMENT AND PLAN OF MERGER",
"Amended and Restated Employment Agreement, by and between Asterias Biotherapeutics, Inc. and Craig Halberstadt",
"Amended and Restated Employment Agreement, by and between Asterias Biotherapeutics, Inc. and Edward Wirth, III",
"Amended and Restated Employment Agreement, by and between Asterias Biotherapeutics, Inc. and Ryan Chavez",
"BioTime Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno-Oncology Asterias Stockholders to Receive 0.71 Shares of BioTime for Each Share of Asterias Biotherapeutics ALAMEDA, CA and FREMONT, CA – - BioTime, Inc. , and Asterias Biotherapeutics, Inc. , today announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Asterias that are not currently owned by BioTime. Asterias stockholders will receive 0.71 shares of BioTime common shares for every share of Asterias common stock and will own approximately 16.2% of the combined company. Subject to customary closing conditions, including approval by the respective shareholders of BioT..." |
|
|